May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Fluocinolone Acetonide Formulated with Sodium Hyaluronate as a Sustained Release Drug Delivery Pellet in the Treatment of Experimental Proliferative Vitreoretinopathy
D. Khalatbari; P. Mruthyunjaya; P. Yang; S. Stinnett; J. Chen; P. Ashton; G.J. Jaffe
Author Affiliations & Notes
  • D. Khalatbari
    Department of Ophthalmology, Duke University, Durham, NC, United States
  • P. Mruthyunjaya
    Department of Ophthalmology, Duke University, Durham, NC, United States
  • P. Yang
    Department of Ophthalmology, Duke University, Durham, NC, United States
  • S. Stinnett
    Department of Ophthalmology, Duke University, Durham, NC, United States
  • J. Chen
    Control Delivery Systems, Inc, Watertown, MA, United States
  • P. Ashton
    Control Delivery Systems, Inc, Watertown, MA, United States
  • G.J. Jaffe
    Control Delivery Systems, Inc, Watertown, MA, United States
  • Footnotes
    Commercial Relationships  D. Khalatbari, None; P. Mruthyunjaya, None; P. Yang, None; S. Stinnett, None; J. Chen, Control Delivery Systems, Inc E; P. Ashton, Control Delivery Systems, Inc E; G.J. Jaffe, Control Delivery Systems, Inc I, C.
  • Footnotes
    Support  NIH Grant EY05722 and Research to Prevent Blindness
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 3009. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Fluocinolone Acetonide Formulated with Sodium Hyaluronate as a Sustained Release Drug Delivery Pellet in the Treatment of Experimental Proliferative Vitreoretinopathy
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      D. Khalatbari, P. Mruthyunjaya, P. Yang, S. Stinnett, J. Chen, P. Ashton, G.J. Jaffe; Fluocinolone Acetonide Formulated with Sodium Hyaluronate as a Sustained Release Drug Delivery Pellet in the Treatment of Experimental Proliferative Vitreoretinopathy . Invest. Ophthalmol. Vis. Sci. 2003;44(13):3009.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Abstract: : Purpose: Proliferative vitreoretinopathy (PVR) is the leading cause of failure of retinal reattachment surgery. Several pharmacological agents and drug delivery methods have been used clinically and experimentally in attempts to prevent PVR formation. In this study we determined whether fluocinolone acetonide (FA) formulated with sodium hyaluronate as a drug delivery pellet effectively inhibits PVR in a rabbit model. Methods: To induce PVR, lensectomy and vitrectomy were performed, and full thickness retinal breaks were created by endodiathermy in the right eye of 28 New Zealand White rabbits. One milligram of FA was compressed with crystalline sodium hyaluronate into a pellet. The pellet was inserted into the vitreous cavity of 12 animals at the time of PVR induction. In the remaining animals (controls), a pellet composed of sodium hyaluronate alone was inserted into the vitreous cavity. The severity of PVR was graded weekly, from weeks 4 to 12 after PVR induction, by two masked observers using indirect ophthalmoscopy. The FA release profile of the pellet was obtained by placing the pellet in buffer, removing daily aliquots, and assaying for FA with high-pressure liquid chromatography. Results: The severity of PVR was significantly lower in treated eyes compared to controls from weeks 5 to 6 (P <= 0.035) and weeks 9 to 12 (P <= 0.022). The number of eyes with moderate to severe retinal detachments was also lower in the treated group. The pellet showed a FA release rate of 200 ug/day for the first 48 hours followed by a continuously decreasing rate with near total release by 10 to 12 days. Conclusions: Fluocinolone acetonide formulated with sodium hyaluronate as a drug delivery pellet significantly reduces the rate of PVR in an experimental model. This FA delivery method may be a useful therapeutic option for the prevention of PVR following retinal reattachment surgery.

Keywords: proliferative vitreoretinopathy • pharmacology • animal model 
© 2003, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept